INSTILLAGEL

3-IN-1LUBRICANT, ANTISEPTIC, ANAESTHETIC

INSTILLAGEL® is a lubricating gel that is used to prevent pain and reduce the risk of infection during insertion of a catheter and other endourethral procedures.1

INSTILLAGEL® contains lidocaine hydrochloride (a local anaesthetic) & chlorhexidine gluconate (an antiseptic).1

UNIQUE TRIPLE ACTION1

  • LUBRICATES the urethra to make the process of catheter insertion smoother

  • PREVENTS PAIN with lidocaine, a local anaesthetic

  • REDUCES THE RISK OF INFECTION with chlorhexidine, an effective antiseptic

LEARN MORE ABOUT
PRODUCT SELECTION

INSTILLAGEL® offers urethral lubrication1,2

  • The gel flows along the entire urethra, providing an even film of lubricant1
  • Urethral folds and passages are lubricated against friction from the instrument, so the risk of injury may be reduced2

Discover how INSTILLAGEL®’s pre-filled syringe design performs

Explore features

Rapid, lasting anaesthetic1

After INSTILLAGEL® application, the anaesthesia effect:

  • Starts to work in 5 minutes

  • Lasts ~20–30 minutes

Works quickly and delivers a sustained effect consistent with procedural needs.

Effective antiseptic1

  • Microbes are killed within
    5–10 minutes
    after INSTILLAGEL® application

  • Chlorhexidine is effective against a wide range of gram-negative and gram-positive
    vegetative bacteria, yeasts, dermatophyte fungi, and lipophilic viruses†

How to use INSTILLAGEL®

†Note that INSTILLAGEL® is inactive against bacterial spores except at elevated temperatures.

For a chlorhexidine-free lubricant, consider JELIDO®

Learn more

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:1

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

for additional safety information and for a link to the Prescribing Information, which discusses:

  • Contraindications in children < 2 years of age and in patients with a known or suspected hypersensitivity to this drug or any component of the formulation.
  • Most serious warnings and precautions regarding: use in urethra only (not for parenteral administration) and immediate systemic hypersensitivity reactions.
  • Other relevant warnings and precautions regarding: use of the lowest effective dose; avoiding contact with eyes and middle ear; familial malignant hyperthermia; carcinogenesis and mutagenesis; excessive hypotensive response; use during early pregnancy (first trimester); and dose reduction in children, debilitated patients, acutely ill patients, and patients with sepsis. Use with caution in patients with: severe shock; sepsis and/or traumatized mucosa at the application site; epilepsy; impaired cardiac conduction; bradycardia; impaired cardiovascular function; impaired hepatic or renal function; and in persons with known drug sensitivities.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

JELIDO® (lidocaine hydrochloride jelly) is indicated for:3

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations;
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy;
    • Proctoscopy and rectoscopy;
    • Tracheal intubation.
  • Symptomatic treatment of pain in connection with cystitis and urethritis.

Consult the Product Monograph for contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-888-550-6060.

†Available in Canada since 2007.

References: 1. INSTILLAGEL® Prescribing Information. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2025. 2. Sperling H, Lümmen G, Rübben H. The use of lubricants in urology. Indications and results. Urologe [A] 2005;44(6):662-666. 3. JELIDO® Product Monograph. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2026.

PENDOPHARM

INSTILLAGEL is a registered trademark of FARCO-PHARMA GmbH, used under license. JELIDO and UROSAFETIP are registered trademarks of Finchley Research & Development Inc., used under license. PENDOPHARM and its logo are registered trademarks of Finchley Research & Development Inc., used under license. *Registered trademarks are the property of their respective owners. © 2026 PENDOPHARM®. All rights reserved.
Publication date: 29-10-2026

Contact us

For any questions about our products or further information about our company, please do not hesitate to contact us.

INSTILLAGEL® and JELIDO® are available at select specialty pharmacies and by special order at most pharmacy outlets.

6111 Royalmount Avenue, Montreal (Quebec), H4P 2T4, CanadaTelephone+1 (514) 340-5045Fax+1 (866) 926-7654 or +1 (514) 733-9684

MED INFO

Toll-free Telephone: +1 (888) 550-6060
Fax: +1 (514) 340-0164
E-mail: [email protected]

PHARMACOVIGILANCE:

By Telephone: +1 (888) 550-6060
By Fax: +1 (866) 551-1939
By E-mail: [email protected]

For Medical and Scientific Information Services, Adverse Event Report, and Customer Service, please visit our website at https://pendopharm.com/contact/.

INSTILLAGEL® important safety information

Indications and clinical use:

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

Contraindications:

  • INSTILLAGEL® must not be used in children under the age of 2
  • Known or suspected hypersensitivity to local anaesthetics of the amide type, to chlorhexidine or to any ingredient in the formulation (e.g., methylparaben, propylparaben etc.)

Most serious warnings and precautions:

INSTILLAGEL® is for urethral use only: Do not use parenterally.

IMMEDIATE SYSTEMIC HYPERSENSITIVITY REACTIONS INCLUDING HYPOTENSION, TACHYCARDIA, SHORTNESS OF BREATH, SKIN ERYTHEMA, AND ANAPHYLAXIS: IN INDIVIDUALS WHO RECEIVED CHLORHEXIDINE GLUCONATE PREPARATIONS APPLIED TOPICALLY TO THE SKIN OR GIVEN INTRAURETHRALLY, INTRANASALLY, OR ON CENTRAL VENOUS CATHETERS IMPREGNATED WITH THE DRUG. DISCONTINUE TREATMENT IMMEDIATELY IF ADVERSE REACTIONS OR HYPERSENSITIVITY OCCUR.

Other relevant warnings and precautions:

  • The lowest dosage that results in effective anaesthesia should be used to avoid high plasma levels and serious adverse effects
  • Avoid contact with eyes and middle ear
  • Potential triggering agent for familial malignant hyperthermia
  • Carcinogenesis and mutagenesis
  • Lidocaine should be used with caution in patients in severe shock
  • Caution in:
    • Patients with sepsis and/or traumatized mucosa at the area of application
    • Patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic or renal function
    • Patients with impaired cardiovascular function
    • Persons with known drug sensitivities
  • Excessive hypotensive response may occur in the presence of severe damage to the urethra
  • Not recommended for use in the first 3 months of pregnancy
  • Reduced doses in children, debilitated patients, acutely ill patients, and patients with sepsis

For more information:

Consult the Prescribing Information for important information relating to adverse events, drug interactions, and dosing information that has not been discussed in this piece. The Prescribing Information is also available by calling 1-888-550-6060.